-
Androgenic steroid action in breast cancer(Post)
By Rachel Bleach, PhD Student, RCSI By the age of 79 years, 1 in 14 women will develop breast cancer (Global Burden of Disease Cancer 2017). Beatson reported
Ferroptosis: A New Frontier in Cancer Therapy(Post)For decades, the primary strategy in cancer treatment has been to trigger apoptosis, a form of programmed cell death, in malignant cells. However, many cancers develop resistance to apoptosis-inducin
Turning Tumors Against Themselves: In Vivo Reprogramming of Cancer Cells into Dendritic Sentinels(Post)Imagine a future where cancer cells, once masters of disguise, are forced to reveal themselves and even train the body's immune system to fight back. This isn't science fiction; it's the groundbreaki
Fc Receptors & Antibody Effector Function(Page) Unconventional T Cells: Already Armed, and No MHC Required(Post)Most immunology is written as though a T cell must first be told what to look for. Three lineages did not read that memo. γδ T cells, invariant NKT cells and MAIT cells leave the thymus with their ef
Fluorescence Resonance Energy Transfer (FRET) Assays: An Insight into Molecular Interactions(Post)Methods · FluorescenceFRET Assays: Principle, Förster Radius and Measurement MethodsFRET transfers energy from an excited donor fluorophore to a nearby acceptor without emitting a photon, and the effi
Esophageal Cancer: Causes, Symptoms, Diagnosis, Treatment, and Prevention(Post)Esophageal cancer is a type of cancer that affects the esophagus, which is the tube that carries food and liquids from your mouth to your stomach. Esophageal cancer can cause many di
AKT Signalling – Mini Review(Post)Protein kinase B or AKT (PKB) is a serine/threonine kinase. In mammals it is comprised of 3 highly homologous isoforms PKBα (Akt1), PKBβ (Akt2), and PKBγ (Akt3) (Manning and Cantley 2007). AKT
인터루킨 8 시그널링(Page) CD47: Overcoming Tumor Evasion Through Macrophage Activation(Post)One of the greatest challenges in cancer therapy is how tumors evade immune detection. Among the mechanisms cancer cells exploit, the CD47 pathway has emerged as a major player in helping
Macrophage, M1 & M2, Polarization and Function(Post)What is a Macrophage? Macrophages are indeed a type of phagocyte, responsible for engulfing and destroying foreign particles and cellular debris. They are larger cells with more cytoplasm an
Uliledlimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About UliledlimabWhat is Uliledlimab?Uliledlimab is a monoclonal antibody targeting CD47, a checkpoint protein that helps tumors evade immune system detection. By blocking CD
Biosimilar Antibodies(Page) Flow Cytometer Set Up Guide for Genieplex Multiplex(Page) Galegenimab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eli
Biosimilar: Expanding Access to Monoclonal Antibody-Based Therapies(Post)1. What is a Biosimilar? A biosimilar is a biologic medical product that is highly similar to an already-approved reference biologic. While minor differences in clinically inactive compon
Fc Receptors Explained: ADCC, ADCP, CDC and the CD32B Brake(Post)An antibody's variable domains decide what it binds. Its Fc decides what happens next — and that is not a detail of formulation, it is half the mechanism. Which Fcγ receptor the constant region engag
Fibroblast Markers(Post)Fibroblasts, essential components of connective tissues, play vital roles in maintaining tissue structure and function. Their remarkable ability to produce and organize the extracellular matrix
A Comprehensive Overview of Cell Death(Post)Cell death is an essential aspect of cellular biology that plays a crucial role in development, homeostasis, and disease. In this blog, we try to focus on mechanisms and various type
Bersanlimab: Revolutionizing Cancer Research with Anti-CD47 Therapeutics(Post)What You Need to Know About BersanlimabWhat is Bersanlimab?Bersanlimab is a cutting-edge anti-CD47 monoclonal antibody designed to disrupt cancer cells' evasion of immune detection.What